Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the FDA has placed a clinical hold on its Phase 2 trial for KVD824, an oral candidate for hereditary angioedema (HAE). The FDA requested further information and refinements to the study protocol without demanding new studies. CEO Andrew Crockett expressed intent to comply with FDA requests, noting that this hold does not affect the development of KVD900, which is preparing for a Phase 3 trial. Historical data show safe dosing of KVD824 in prior studies, with no serious adverse events reported.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the appointment of Nancy Stuart to its Board of Directors, effective March 18, 2021. Stuart, currently COO at Concert Pharmaceuticals, brings over 25 years of experience in the biopharmaceutical industry. CEO Andrew Crockett highlighted her strategic and operational expertise as valuable for the company's transition to a commercial-stage organization focusing on oral treatments for hereditary angioedema (HAE). KalVista is advancing clinical-stage assets, including KVD900, an oral therapy for acute HAE attacks, which recently showed positive Phase 2 trial results.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) provided a Q3 fiscal update ending January 31, 2021, highlighting significant progress in treating hereditary angioedema (HAE) with KVD900 and KVD824. KVD900 showed strong Phase 2 results, significantly outperforming placebo on multiple endpoints. The company closed a public offering, raising approximately $222.5 million. However, revenue fell to $0 from $1.6 million due to the expiration of the Merck Option Agreement. Net loss increased to $10.1 million, while cash reserves decreased to $50.3 million, attributed to R&D spending.
KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 9:20 a.m. ET. A live webcast will be available on the company's website, along with an audio archive for 30 days post-event.
KalVista focuses on developing small molecule protease inhibitors, including KVD900 for acute hereditary angioedema (HAE) attacks and KVD824 for prophylactic HAE treatment, with significant clinical trial advancements in early 2021.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has successfully closed its upsized public offering, selling 6,181,250 shares at $36.00 each, raising approximately $222.5 million in gross proceeds. This includes the underwriters' option for an additional 806,250 shares. Jefferies LLC, Stifel, Nicolaus & Company, and Cantor Fitzgerald acted as joint book-running managers. The offering is registered with the SEC and follows prior effective registration statements. KalVista specializes in developing small molecule protease inhibitors for critical diseases, including hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has priced its upsized public offering of 5,375,000 shares of common stock at $36.00 per share, projecting gross proceeds of $193.5 million. The offering will close around February 16, 2021, pending customary conditions. An additional 806,250 shares may be purchased by underwriters. Funds will support the Phase 3 trial of KVD900, Phase 2 trial of KVD824, and development of oral Factor XIIa programs. Jefferies, Stifel, and Cantor Fitzgerald are managing the offering.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) plans to offer 4,500,000 shares of common stock in an underwritten public offering, with an additional 675,000 shares available for underwriters. The capital raised aims to finance a Phase 3 trial of KVD900 and a Phase 2 trial of KVD824, along with the development of its oral Factor XIIa programs. The offering is contingent upon market conditions and follows a shelf registration statement effective since December 2018. Jefferies, Stifel, and Cantor Fitzgerald will manage the offering.
KalVista Pharmaceuticals (NASDAQ: KALV) announced positive topline data from a Phase 2 trial of KVD900, an oral treatment for hereditary angioedema (HAE) attacks. The trial showed statistically significant efficacy, with KVD900 resulting in a 15% rate of rescue medication use compared to 30% for placebo at 12 hours (p=0.001). Symptom relief onset was significantly faster with KVD900, taking 1.6 hours versus 9 hours for placebo (p0.0001). No serious adverse events were reported, showcasing KVD900's favorable safety profile. A presentation of the trial data will be available on their website.
KalVista Pharmaceuticals (NASDAQ: KALV) reported no revenue for the second fiscal quarter ended October 31, 2020, down from $3.9 million the previous year, due to the expiration of the Merck Option Agreement. A net loss of $10.4 million, or $(0.58) per share, was observed, compared to a loss of $5.9 million, or $(0.33) per share, in the same quarter last year. The company completed patient treatment in a Phase 2 trial for KVD900, with data expected in Q1 2021. Additionally, an IND submission for KVD824 is anticipated in Q1 2021, aiming for a twice-daily oral treatment for hereditary angioedema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two investor conferences: Stifel 2020 Virtual Healthcare Conference on November 16 at 10:40 a.m. EST and Jefferies Virtual London Healthcare Conference on November 19 at 3:50 p.m. GMT. A live webcast of the presentations will be available on the company's website, with an audio archive accessible for 30 days afterward. The company focuses on small molecule protease inhibitors targeting diseases like hereditary angioedema and diabetic macular edema, with ongoing clinical trials for treatments such as KVD900 and KVD824.